Clinical Trial

A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia

Study acronym: KAPPTIVATE1001
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to see how feasible it is to enroll participants with schizophrenia and for them to complete the study/assessments. It will also assess how safe and tolerable aticaprant is when compared with placebo in participants with schizophrenia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-05-22; most recent amendment 2026-07-02.
Trial Details
NCT Number NCT07615426
Lead Sponsor Janssen Research & Development, LLC
Conditions Schizophrenia
Enrollment 64 participants
Start Date 2026-03-02
Primary Completion 2027-06-21 (estimated)
Study Completion 2027-07-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-06